StevenMHerschMDPhD

Movement Disorder, Neurodegenerative

Vice President, Clinical Research, Eisai Inc. and Professor of Neurology, Harvard Medical School, Massachusetts General Hospital

Join to view full profile

Dr. Hersch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hersch's full profile

Already have an account?

Office
Neurology Business Group
200 Metro Boulevard
Nutley, NJ 07110
Phone+1 201-746-2023
Is this information wrong?

Summary

Dr. Steven Hersch is a neurologist in Boston, MA and is affiliated with Massachusetts General Hospital, Harvard Medical School. He received his medical degree from Boston University School of Medicine and has been in practice 33 years. He specializes in neurodegenerative disorders and is experienced in memory disorders, movement disorders, and Huntington's disease and in clinical development of experimental therapeutics.

Education & Training

Emory University School of MedicineResidency, Neurology, 1985 - 1990
Boston University School of MedicineClass of 1984

Certifications & Licensure

MA State Medical License 2001 - 2024
NH State Medical License 2021 - 2023
ME State Medical License 2021 - 2023
RI State Medical License 2021 - 2022
GA State Medical License 1987 - 2005
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Creatine Therapy for Huntington's Disease Start of enrollment: 2001 Oct 01
Completed
Phase 1, Phase 2
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) Start of enrollment: 2005 Aug 01
Completed
Phase 2
Creatine Safety and Tolerability in Premanifest HD: PRECREST Start of enrollment: 2007 Dec 01
Completed
Phase 2
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
Terminated
Phase 3
Creatine Safety & Tolerability in Huntington's Disease Start of enrollment: 2005 Apr 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease.
Hilda T Maibach, Michael J Brownstein, Steven M Hersch, Karen E Anderson, Debra E Itzkowitz, Eve M Damiano, Neal G Simon> ;Journal of Personalized Medicine. 2022 Sep 22
Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.
Douglas R Langbehn, Elisabeth M Fine, Andreas Meier, Steven Hersch> ;Movement Disorders. 2022 May 1
1 citations
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease.
Andrew McGarry, Peggy Auinger, Karl D Kieburtz, Amy-Lee Bredlau, Steven M Hersch, H Diana Rosas> ;Neurology. Clinical Practice. 2022 Apr 1
2 citations
A natural history study to track brain and spinal cord changes in individuals with Friedreich's ataxia: TRACK-FA study protocol.
Nellie Georgiou-Karistianis, Louise A Corben, Kathrin Reetz, Isaac M Adanyeguh, Manuela Corti, Dinesh K Deelchand, Martin B Delatycki, Imis Dogan, Rebecca Evans, Jenni...> ;Plos One. 2022 Jan 1
4 citations
Impaired Cerebrovascular Reactivity in Huntington's Disease.
Suk-Tak Chan, Nathaniel D. Mercaldo, Kenneth K. Kwong, Steven M. Hersch, H. D. Rosas> ;Frontiers in Physiology. 2021 Jul 21
10 citations
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
Michael J Brownstein, Neal G. Simon, Jeffrey D. Long, Jon W. Yankey, Hilda T Maibach, Merit Cudkowicz, Christopher S. Coffey, Robin Conwit, Codrin Lungu, Karen E. Ande...> ;Journal of Clinical Medicine. 2020 Nov 16
16 citations
Association of Dilated Perivascular Spaces and Disease Severity in Patients With Huntington Disease.
Suk-Tak Chan, Nathaniel D. Mercaldo, Bernard Ravina, Steven M. Hersch, H. D. Rosas> ;Neurology. 2020 Oct 26
9 citations
Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials.
Douglas R. Langbehn, Steven M. Hersch> ;Movement Disorders. 2020 Jul 20
6 citations
Double Tubular Contractile Structure of the Type VI Secretion System Displays Striking Flexibility and Elasticity
Maria Silvina Stietz, Xiaoye Liang, Megan Wong, Steven J. Hersch, Tao G. Dong> ;Journal of Bacteriology. 2019 Dec 6
15 citations
The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting.
Ian A. Blair, Jennifer M. Farmer, Steven M. Hersch, Jane Larkindale, David A. Lynch, Jill S. Napierala, Marek Napierala, R. Mark Payne, S. H. Subramony> ;Future Science OA. 2019 Jun 28
1 citations
The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation.
Elise Kayson, Shirley Eberly, Karen E. Anderson, Karen Marder, Ira Shoulson, David Oakes, Anne B. Young, Kevin Biglan, Steven M. Hersch> ;Journal of Huntington's Disease. 2019 Jan 1
13 citations
Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease
Christopher D. Stephen, Judy Hung, Giovanni Schifitto, Steven M. Hersch, H. Diana Rosas> ;Movement Disorders Clinical Practice. 2018 May 1
28 citations
Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease.
H. D. Rosas, Paul Wilkens, David H. Salat, Nathaniel D. Mercaldo, Mark Vangel, Anastasia Yendiki, Steven M. Hersch> ;Neuroimage. Clinical. 2018 Jan 1
80 citations
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.
Scott Schobel, Giuseppe Palermo, Peggy Auinger, Jeffrey D. Long, Shiyang Ma, Omar Khwaja, Dylan Trundell, Merit Cudkowicz, Steven M. Hersch, Cristina Sampaio, E. Ray D...> ;Neurology. 2017 Dec 12
43 citations
The CREST-E study of creatine for Huntington disease: A randomized controlled trial.
Steven M. Hersch, Giovanni Schifitto, David Oakes, Amy-Lee Bredlau, Catherine M. Meyers, Richard Nahin, H. D. Rosas, Coordinators> ;Neurology. 2017 Aug 8
88 citations
KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients
Luisa Quinti, Sharadha Dayalan Naidu, Ulrike Träger, Xiqun Chen, Kimberly B. Kegel-Gleason, David Llères, Colúm Connolly, Vanita Chopra, Cho Low, Sébastien Moniot, Ell...> ;Proceedings of the National Academy of Sciences of the United States of America. 2017 Jun 6
21 citations
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
Vanita Chopra, Luisa Quinti, Prarthana Khanna, Paolo Paganetti, Rainer Kuhn, Anne B. Young, Aleksey G. Kazantsev, Steven M. Hersch> ;Journal of Huntington's Disease. 2016 Jan 1
37 citations
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials
Kevin M. Biglan, Ira Shoulson, Karl Kieburtz, David Oakes, Elise Kayson, M. Aileen Shinaman, Hongwei Zhao, Megan Romer, Anne Young, Steven M. Hersch, J. B. Penney, Kar...> ;JAMA Neurology. 2016 Jan 1
55 citations
A systems-level “misunderstanding”: the plasma metabolome in Huntington's disease
H. D. Rosas, Gheorghe Doros, Swati S. Bhasin, Beena E. Thomas, Sona Gevorkian, Keith Malarick, Wayne R. Matson, Steven M. Hersch> ;Annals of Clinical and Translational Neurology. 2015 May 28
27 citations
Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington’s Disease
K. Lakshmi Narayanan, Vanita Chopra, H. Diana Rosas, Keith Malarick, Steven J. Hersch> ;Molecular Neurobiology. 2016 May 1
78 citations
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial
D. Angus, C. Herd, Cameron Stone, Julie C. Stout, Marguerite Wieler, Ralf Reilmann, Craig W. Ritchie, Earl Ray Dorsey, K. Helles, Elise Kayson, David Oakes, H. D. Rosa...> ;The Lancet. Neurology. 2015 Jan 1
37 citations
Altered selenium status in Huntington's disease: Neuroprotection by selenite in the N171-82Q mouse model
Zhen Lu, Eileen S. Marks, Jianfang Chen, Jenna Moline, Lorraine F. Barrows, Merl F. Raisbeck, Irene Volitakis, Robert A. Cherny, Vanita Chopra, Ashley I. Bush, Steven ...> ;Neurobiology of Disease. 2014 Nov 1
69 citations
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.
H. D. Rosas, Gheorghe Doros, Sona Gevorkian, Keith Malarick, Martin Reuter, Jean-Philippe Coutu, Tyler D. Triggs, Paul Wilkens, Wayne R. Matson, David H. Salat, Steven...> ;Neurology. 2014 Mar 11
115 citations
Iron accumulates in Huntington's disease neurons: protection by deferoxamine.
Jianfang Chen, Eileen S. Marks, Barry Lai, Zhaojie Zhang, James A. Duce, Linh Q Lam, Irene Volitakis, Ashley I. Bush, Steven M. Hersch, Jonathan H. Fox> ;Plos One. 2013 Oct 11
8 citations
HTRF analysis of soluble huntingtin in PHAROS PBMCs
Miriam Moscovitch-Lopatin, Rachel E. Goodman, Shirley Eberly, James J. Ritch, H. Diana Rosas, Samantha Matson, Wayne R. Matson, David Oakes, Anne B. Young, Ira Shoulso...> ;Neurology. 2013 Sep 24
Join now to see all

Journal Articles

Complex Spatial and Temporally Defined Myelin and Axonal Degeneration in Huntington Disease
S M Hersch, H D Rosas, ScienceDirect

Press Mentions

Minnesota Farm Couple Raising Sheep to Help in Treating Human DiseaseJune 22nd, 2017
Fearing Punishment for Bad GenesApril 7th, 2014
Assay Shown to Be Effective in Measuring Levels of Mutant Huntingtin ProteinAugust 29th, 2013
Join now to see all